Patents by Inventor David ROTLLANT POZO

David ROTLLANT POZO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING BEHAVIOR ALTERATIONS
    Publication number: 20200323828
    Abstract: Provided herein are methods for treating behavior alterations using KDM1A inhibitors, particularly 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine.
    Type: Application
    Filed: August 3, 2018
    Publication date: October 15, 2020
    Inventors: Tamara MAES, David ROTLLANT POZO, Christian GRIÑÁN FERRE, Mercè PALLÀS LLIBERIA, Roser NADAL ALEMANY, Antonio ARMARIO GARCÍA
  • Method of treating multiple sclerosis employing a LSD1-inhibitor
    Patent number: 10780081
    Abstract: Provided herein are methods for treating multiple sclerosis using (?) 5-((((trans)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine, or a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: September 22, 2020
    Assignee: Oryzon Genomics, S.A.
    Inventors: Tamara Maes, Cristina Mascarò Crusat, David Rotllant Pozo
  • METHOD OF TREATING MULTIPLE SCHLEROSIS EMPLOYING A LSD1-INHIBITOR
    Publication number: 20190083469
    Abstract: Provided herein are methods for treating multiple sclerosis using (?) 5-((((trans)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine, or a pharmaceutically acceptable salt or solvate thereof.
    Type: Application
    Filed: June 9, 2017
    Publication date: March 21, 2019
    Inventors: Tamara MAES, Cristina MASCARÒ CRUSAT, David ROTLLANT POZO
  • BIOMARKERS ASSOCIATED WITH LSD1 INHIBITORS AND USES THEREOF
    Publication number: 20180284095
    Abstract: The invention relates to biomarkers associated with LSD1 inhibitors and uses thereof to assess target engagement and to follow patient response to treatment. The invention further relates to novel therapeutic uses for LSD1 inhibitors based on said biomarkers.
    Type: Application
    Filed: June 10, 2016
    Publication date: October 4, 2018
    Inventors: Tamara MAES, Cristina MASCARÓ CRUSAT, David ROTLLANT POZO